A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.

Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Irene Grifoni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Giambattista Bertani(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Barbara Sarina(IRCCS Humanitas Research Hospital), Maria Cristina Pasquini(Azienda Ospedaliera Ospedale Maggiore)
PubMed
March 1, 2005
Cited by 29

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
|Leukemia|2018|250